Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
A randomised, open-label, parallel group study to evaluate the management of rosiglitazone-related fluid retention by investigating the effect of diuretics on plasma volume in subjects with type 2 diabetes mellitus treated for twelve weeks with rosiglitazone 4mg bd in addition to background anti-diabetic agents.
Age
35–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects with type 2 diabetes.
Stable FPG of \>=7.0 and \<=12.0mmol/L.
Subjects had to have been established on SU treatment or SU+MET treatment for at least 2 months.